Bandad, S & Habibian, M 2025, Effect of high-intensity interval training and fisetin on the gene expression of NLRP3 and IL18 in kidney tissue of mice with Type 2 diabetes. Journal of Shahid Sadoughi University of Medical Sciences, 33(7): 9205–9215.
Chakramurty, A, Rahma Dinni, A, Silvia, I, Laras Cantika, A & Dyah Kencono Wungu, C 2025, Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns. ADMET and DMPK, 13(5), Article 2956. https://doi.org/10.5599/admet.2956.
Dong, W, Jia, C, Li, J, Zhou, Y, Luo, Y, Liu, J et al. 2022, Fisetin Attenuates Diabetic Nephropathy-Induced Podocyte Injury by Inhibiting NLRP3 Inflammasome. Frontiers in Pharmacology, 13: 783706.
Ge, C, Xu, M, Qin, Y, Gu, T, Lou, D, Li, Q, et al. 2019, Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation. Food & Function, 10(5), 2970–2985.
Hou, Y, Lin, S, Qiu, J, Sun, W, Dong, M, Xiang, Y et al. 2020, NLRP3 Inflammasome negatively regulates podocyte autophagy in diabetic nephropathy. Biochemical and Biophysical Research Communications, 521(3), 791–798.
Huang, G, Zhang, Y, Zhang, Y & Ma, Y 2022, Chronic kidney disease and NLRP3 inflammasome: pathogenesis, development and targeted therapeutic strategies. Biochemistry and Biophysics Reports, 33, 101417.
Jabardo-Camprubí, G, Donat-Roca, R, Sitjà-Rabert, M, Milà-Villarroel, R & Bort-Roig, J 2020, Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: A systematic review and meta-analysis. Physiology & Behavior, 215: 112786.
Khoramipour, K, Rajizadeh, MA, Akbari, Z & Arjmand, M 2024, The effect of high-intensity interval training on type 2 diabetic muscle: a metabolomics-based study. Heliyon, 10(15): e34917.
Qian, X, Lin, S, Li, J, Jia, C, Luo, Y, Fan, R et al. 2023, Fisetin ameliorates diabetic nephropathy‐induced podocyte injury by modulating Nrf2/HO‐1/GPX4 signaling pathway. Evidence-Based Complementary and Alternative Medicine, 2023: 9331546.
Madina, K, Baxtiyor, S, Mexriniso, I, Muslima, A, Iroda, A, Erkin, K & Zavqiddin, R 2025, AI-driven risk prediction models for hypertensive emergencies in diabetic patients: validation in multi-ethnic cohorts. Revista Latinoamericana de Hipertension, 20(8): 561-567.
Maratovna, DK, Abdusamatovna, MS, Nusratovna, AN, Yuldashevich, YI & Ibrohimov, KI 2024, pH-responsive nanogels for controlled release of insulin in diabetes management. Procedia Environmental Science, Engineering and Management, 11 (2): 197-208.
Narulita, S, Sumpat, D, Avoi, R, Ping, NPT, Qolina, E & Winahayu, NE 2026, Metabolic and cannabinoid crosstalk between diabetes mellitus and skin aging: molecular pathways, fibroblast senescence, and therapeutic strategies.
Revista Latinoamericana de Hipertensión, 21(1): 37-44.
http://doi.org/10.5281/zenodo.18626404.
Shakibi, MR, Atapour, J, Kalantari, B & Namjoo, B 2003, Evaluation of frequency and risk factors of soft tissue rheumatism of upper limbs in diabetic patients in Kerman in 2001. Avicenna Journal of Clinical Medicine, 10(3), 20–26.
Yang, M, Wang, X, Han, Y, Li, C, Wei, L, Yang, J et al. 2021, Targeting the NLRP3 inflammasome in diabetic nephropathy. Current Medicinal Chemistry, 28(42): 8810–8824.
Wang, L, Zhu, L, Wang, F, Dong, L, Liu, Z, Chen, F & Jiang, J 2025, Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin.
ADMET and DMPK, 13(2): 2582, DOI:
https://doi.org/10.5599/admet.2582.
Zhao, W, Zhou, L, Novák, P, Shi, X, Lin, CB, Zhu, X et al. 2022, Metabolic dysfunction in the regulation of the NLRP3 inflammasome activation: A potential target for diabetic nephropathy. Journal of Diabetes Research, 2022: 2193768.
Zheng, L, Qin, R, Rao, Z & Xiao, W 2023, High-intensity interval training induces renal injury and fibrosis in type 2 diabetic mice. Life Sciences, 324: 121740.